Blue Earth Therapeutics announces first participant dosed in Phase 1 clinical trial investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in metastatic castration-resistant prostate cancer

Blue Earth Therapeutics (with UCL) initiated a UCL-sponsored Phase 1 clinical trial (NCT07414940) of Actinium-225 (225Ac) rhPSMA-10.1 Injection for PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC) after progression on prior therapy. The study aims to assess safety/tolerability and anti-tumor activity, and to inform dose selection for later research. This advances the company’s second alpha-emitting radiopharmaceutical candidate alongside its ongoing Phase 2 Lutetium (177Lu) rhPSMA-10.1 program, supporting a targeted precision-radioligand treatment strategy while focusing on toxicity profiling.

Analysis

This is more useful as a platform de-risking event than as a near-term earnings driver. In radiopharma, the equity value usually rerates on three things: clean safety, reproducible manufacturing, and evidence the isotope can be scaled cheaply enough to support commercial dose intensity. If 225Ac can be delivered without hematologic blowback, it strengthens the case that PSMA can be a multi-asset franchise rather than a single-drug story; if not, the market will keep treating alpha programs as science projects and the terminal value uplift evaporates.

Second-order winners are the picks-and-shovels around PSMA adoption: diagnostics that increase patient identification, isotope supply chain names, and CDMOs with radiochemistry capacity. The more important commercial question is whether this expands the total treated population or simply shifts sequencing after beta therapy failure. If it is only a salvage niche, the upside to addressable market is modest and incumbents may face less displacement than bulls assume.

The main tail risk is CMC and toxicity, not clinical rhetoric. Phase 1 readouts can look encouraging for months and still fail on dose-limiting marrow suppression, dosimetry variability, or batch-to-batch isotope constraints. Over the next 1-3 months, the stock reaction will likely be driven by sentiment; over 6-18 months, the real catalysts are dose-selection quality, partnering terms, and whether regulators accept a clean expansion path. Consensus is probably overconfident on platform optionality and underappreciating how narrow the commercial window may remain if alpha is too toxic or too hard to manufacture at scale.

Key Decisions for Investors

• PPLI: stand aside on the headline; treat this as a watch item until first dose-escalation safety data. Fade any >15% move on no new human efficacy signal.
• Long LNTH vs short NVS for 1-3 months if you want a PSMA basket expression: higher PSMA utilization should support imaging pull-through faster than it threatens incumbent therapy share.
• If you want cleaner optionality, consider a small long in a radiopharma infrastructure proxy only after confirmation that the trial is not constrained by isotope supply or dosimetry problems; otherwise skip the trade.
• Set an alert for dose-limiting toxicity or manufacturing commentary in the Phase 1 update; either would be a thesis falsifier and likely compress the entire PSMA alpha-platform complex.